Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of Baloxavir Marboxil in Combination With Standard-of-Care Neuraminidase Inhibitor in Hospitalized Participants With Severe Influenza

Next Previous
Search
Trial Profile

A Phase III, Randomized, Double-Blind Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of Baloxavir Marboxil in Combination With Standard-of-Care Neuraminidase Inhibitor in Hospitalized Participants With Severe Influenza

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baloxavir-marboxil (Primary) ; Oseltamivir; Peramivir; Zanamivir
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms FLAGSTONE
  • Sponsors Roche

    • Most Recent Events

    • 01 May 2022 Primary endpoint (Time to Clinical Improvement) has not been met as per results published in The Lancet Infectious Diseases
    • 01 May 2022 Results published in The Lancet Infectious Diseases
    • 07 Jun 2020 This trial has been completed in France (Global End Date: 16 Mar 2020), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top